High Stakes, New Strategies: Tackling Severe Alcohol-Associated Hepatitis

Nov 10 2025
Convention Center: Ballroom B, Level 3
2:00 PM - 3:30 PM

World Class Speakers

Maddie Kubiliun, MD, MPH
Abstract Presenter

Maddie Kubiliun, MD, MPH

UT Southwestern
Helena Cortez-Pinto, MD, PhD, FAASLD
Moderator

Helena Cortez-Pinto, MD, PhD, FAASLD

Faculdade de Medicina, Universidade de Lisboa
Winston Dunn, MD, FAASLD
Moderator

Winston Dunn, MD, FAASLD

University of Kansas Medical Center

Description

In this session, presenters will explore emerging research on alcohol-associated liver disease (ALD), with a focus on severe alcohol-associated hepatitis (SAH). The session will highlight long-term outcomes following hospitalization and early liver transplantation for SAH, as well as introduce a novel therapeutic approach to its treatment. Additionally, it will examine a newly identified genetic risk modifier for ALD and investigate the potential influence of cannabis use on disease risk. Together, these abstracts aim to deepen understanding of disease mechanisms, treatment strategies, and risk factors in ALD.

Journey Maps

Presentations

2:45 PM - 3:00 PM
Apr 29 2026
Washington, D.C.

Reverse Transcriptase Inhibitors Are Associated with Reduced Liver-Related Complications in AUD: Establishing a Pathogenic Role of Endogenous Retroviruses in AH and ALD

Maddie Kubiliun, MD, MPH , Abstract Presenter
Hepatitis

Objectives

  • Describe long-term outcomes following hospitalization and early liver transplant for severe alcohol-associated hepatitis
  • Discuss the potential for cannabis use as a risk modifier in ALD
  • Describe a novel genetic risk modifier for ALD